US Flag logoAn official website of the United States government
SLCO1B1 Variants and Methotrexate Clearance
dbGaP
Data Resource:  dbGaP
Point of Contact:  
Mary V. Relling, PharmD,  
Project

About This Dataset
Methotrexate plasma concentration is related to its clinical effects. To identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL), we performed a genome-wide analysis (GWAS) of 500,568 germline single-nucleotide polymorphisms (SNPs) in 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m2. SNPs were validated in an independent cohort of 206 patients.
Core Data Elements
Number of Cases
434
Case Sex
Not Reported (434)
Case Age At Diagnosis
Pediatric and Young Adult (<40 years) (434)
Case Race
Asian (5); Black or African American (73); Other (41); White (315)
Case Ethnicity
Not Reported (434)
Case Disease Diagnosis
Acute Lymphoblastic Leukemia (434)
Case Tumor Site
Not Reported (434)
Additional Data Elements
DBGAP STUDY IDENTIFIER
CASE AGE AVERAGE
5.9
CASE AGE MAXIMUM
18.9
CASE AGE MINIMUM
1
Grant Information
P30CA021765
Pharmacokinetics Shared Resources Core
U01GM092666
PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children
Published In
https://doi.org/10.1200/jco.2008.20.4156
Charts
Not Reported (434)
434Not Reported